BioCentury
ARTICLE | Product Development

Preprint study renews cancer fears for CRISPR-based therapies

Another preprint paper has investors questioning whether CRISPR causes cancer

November 5, 2019 1:43 AM UTC
Updated on Nov 9, 2019 at 1:10 AM UTC

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a new paper adds validation to claims that CRISPR-Cas9 may cause cancer.

Although CRISPR is progressing in the clinic, safety concerns still loom and investors are highly sensitive to any safety red flags...